David Ferry

16.3k total citations · 4 hit papers
126 papers, 9.2k citations indexed

About

David Ferry is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, David Ferry has authored 126 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Pulmonary and Respiratory Medicine, 66 papers in Oncology and 32 papers in Molecular Biology. Recurrent topics in David Ferry's work include Colorectal Cancer Treatments and Studies (44 papers), Gastric Cancer Management and Outcomes (43 papers) and Lung Cancer Treatments and Mutations (24 papers). David Ferry is often cited by papers focused on Colorectal Cancer Treatments and Studies (44 papers), Gastric Cancer Management and Outcomes (43 papers) and Lung Cancer Treatments and Mutations (24 papers). David Ferry collaborates with scholars based in United States, United Kingdom and Germany. David Ferry's co-authors include Hartmut Glossmann, Eric Van Cutsem, David Cunningham, Jaffer A. Ajani, Atsushi Ohtsu, Kei Muro, A. Göll, Josep Tabernero, H. Wilke and Michael Emig and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

David Ferry

126 papers receiving 8.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

2014 1.7k citations Kei Muro, Eric Van Cutsem et al. profile →
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

2012 986 citations Eric Van Cutsem, Josep Tabernero et al. Journal of Clinical Oncology profile →
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

2013 547 citations Ian Chau, David Ferry et al. profile →
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

2013 379 citations Atsushi Ohtsu, Jaffer A. Ajani et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
David Ferry	4.4k	3.9k	2.7k	2.1k	1.3k	126	9.2k
Koji Yamaguchi	6.1k 1.4×	2.9k 0.7×	2.2k 0.8×	6.5k 3.1×	1.3k 1.0×	484	11.9k
Masato Sakon	2.8k 0.6×	1.6k 0.4×	3.4k 1.3×	2.4k 1.1×	539 0.4×	383	9.9k
O. Joe Hines	4.3k 1.0×	1.4k 0.3×	2.7k 1.0×	2.7k 1.3×	352 0.3×	215	8.6k
Simon Law	2.1k 0.5×	4.9k 1.2×	3.0k 1.1×	6.1k 2.9×	517 0.4×	275	10.5k
David P. Kelsen	8.9k 2.0×	6.3k 1.6×	3.1k 1.2×	4.2k 2.0×	404 0.3×	292	14.6k
Stefano Cascinu	11.2k 2.6×	7.3k 1.8×	4.2k 1.6×	3.4k 1.6×	330 0.3×	648	18.3k
Jordan M. Winter	7.2k 1.6×	3.5k 0.9×	3.0k 1.1×	5.2k 2.5×	401 0.3×	218	11.2k
Thomas Schmidt	1.6k 0.4×	1.4k 0.4×	1.6k 0.6×	1.9k 0.9×	419 0.3×	251	6.0k
Yoshitaka Yamamura	2.6k 0.6×	7.7k 1.9×	1.7k 0.6×	4.2k 2.0×	299 0.2×	164	10.8k
Howard A. Reber	6.2k 1.4×	2.0k 0.5×	2.6k 1.0×	5.1k 2.4×	155 0.1×	266	11.0k

Countries citing papers authored by David Ferry

Since Specialization

Citations

This map shows the geographic impact of David Ferry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Ferry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Ferry more than expected).

Fields of papers citing papers by David Ferry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Ferry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Ferry. The network helps show where David Ferry may publish in the future.

Co-authorship network of co-authors of David Ferry

This figure shows the co-authorship network connecting the top 25 collaborators of David Ferry. A scholar is included among the top collaborators of David Ferry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Ferry. David Ferry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chau, Ian, Nicolas Penel, Andres O. Soriano, et al.. (2020). Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. Cancers. 12(10). 2985–2985. 22 indexed citations

Spigel, David R., Robert M. Jotte, John Nemunaitis, et al.. (2020). Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2). Journal of Thoracic Oncology. 16(2). 327–333. 36 indexed citations

Paik, Paul K., Ronglai Shen, Michael F. Berger, et al.. (2017). A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. Clinical Cancer Research. 23(18). 5366–5373. 115 indexed citations

Tabernero, Josep, Atsushi Ohtsu, Kei Muro, et al.. (2017). Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Molecular Cancer Therapeutics. 16(10). 2215–2222. 34 indexed citations

Ferry, David, Lucinda Billingham, Hugh Jarrett, et al.. (2017). Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer. 83. 302–312. 15 indexed citations

Arkenau, Hendrik‐Tobias, Johanna C. Bendell, Roy S. Herbst, et al.. (2017). Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study. Annals of Oncology. 28. iii144–iii145. 2 indexed citations

Fuchs, Charles S., Josep Tabernero, Jiří Tomášek, et al.. (2016). Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. British Journal of Cancer. 115(8). 974–982. 57 indexed citations

Tabernero, Josep, Jiří Tomášek, Rodolfo Passalacqua, et al.. (2013). Regard Phase 3, Randomized Trial of Ramucirumab in Patients with Metastatic Gastric or Gej Adenocarcinoma Following Progression on First-Line Chemotherapy. Annals of Oncology. 24. iv14–iv14. 2 indexed citations

Ferry, David, Paul Ruff, Radek Lakomý, et al.. (2013). Time Course of Adverse Events in the Velour Trial. Annals of Oncology. 24. iv36–iv36. 1 indexed citations

10.

Ruff, Paul, David Ferry, Demetris Papamichael, et al.. (2013). Observed Benefit of Aflibercept in MCRC Patients ≥65 Years Old: Results of a Prespecified Age-Based Analysis of the Velour Study. Annals of Oncology. 24. iv18–iv18. 4 indexed citations

11.

Nicolson, M., Dean A. Fennell, David Ferry, et al.. (2013). Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial. Journal of Thoracic Oncology. 8(7). 930–939. 49 indexed citations

12.

Cutsem, Eric Van, Josep Tabernero, Radek Lakomý, et al.. (2012). Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. Journal of Clinical Oncology. 30(28). 3499–3506. 986 indexed citations breakdown →

13.

Raouf, Sherif, John Bridgewater, Richard Ellis, et al.. (2012). Use of bevacizumab in the treatment of metastatic colorectal cancer. British Journal of Hospital Medicine. 73(1). 25–30. 1 indexed citations

14.

Goss, Glenwood, David Ferry, Scott A. Laurie, et al.. (2007). B3-02: Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status (INSTEP). Journal of Thoracic Oncology. 2(8). S340–S340. 12 indexed citations

15.

Boden, William E., Robert A. O’Rourke, Michael H. Crawford, et al.. (1999). Outcomes in Patients with Acute Non-Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy. Survey of Anesthesiology. 43(5). 253–254. 236 indexed citations

16.

Ferry, David, Robert A. O’Rourke, Alvin Blaustein, et al.. (1998). Design and Baseline Characteristics of the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) Trial fn1fn1This study was supported by the Department of Veterans Affairs Cooperative Studies Program, Palo Alto, California and Washington, D.C. and by a grant from Hoechst Marion Roussel, Inc., Kansas City, Missouri.. Journal of the American College of Cardiology. 31(2). 312–320. 19 indexed citations

17.

Ferry, David, et al.. (1995). The Genetic Basis of Resistance to Cancer Chemotherapy. Annals of Medicine. 27(2). 157–167. 24 indexed citations

18.

Ferry, David, et al.. (1994). Dexniguldipine-HCl is a potent allosteric inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells. European Journal of Pharmacology Molecular Pharmacology. 288(1). 105–114. 27 indexed citations

19.

Glossmann, Hartmut, et al.. (1987). Resolving the structure of the Ca2+ channel by photoaffinity labelling. Trends in Pharmacological Sciences. 8(3). 95–100. 47 indexed citations

20.

Kern, Morton J., et al.. (1985). Regional coronary vasoconstriction after combined beta-adrenergic and calcium channel blockade in patients with coronary artery disease. Journal of the American College of Cardiology. 5(6). 1438–1450. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact